Market Cap: 42.5467B; Large Cap
P/E Ratio: 40.16; Fwd: 36.9
EPS (TTM): $13.43
Div. Yield: N/A

IDXXNASDAQ— IDEXX Laboratories Inc Price & Analysis

IDEXX Laboratories Inc

HEALTHCARE — DIAGNOSTICS & RESEARCH

$544.32

+$4.95+0.92%

Market Cap: 42.5467B; Large Cap
P/E Ratio: 40.16; Fwd: 36.9
EPS (TTM): $13.43
Div. Yield: N/A

Technical Summary

RSI (14)45.72Neutral

SMA (50)$554.49Bearish

SMA (200)$622.11Bearish

MACD-1.8883Bearish

Bollinger$527.87 – $579.40Mid

Stochastic17.14Oversold

Theo Outlook

IDEXX Laboratories presents a bullish thesis supported by a market capitalization of $44.76 billion, a trailing P/E of 41.85, EPS of $13.56, and robust quarterly revenue growth of 14.3% alongside 17.2% earnings growth year-over-year. The premium valuation reflects strong profitability margins of 24.6% and operating margins of 31.8%, positioning the company for continued outperformance in the diagnostics sector. Forward P/E of 38.46 suggests analysts anticipate sustained earnings expansion.

Key catalysts include accelerating adoption of companion animal diagnostics, expansion into livestock and water testing markets, and consistent earnings momentum with the latest quarter ending March 31, 2026 showing positive growth trends. Product innovation in veterinary reference labs and point-of-care testing, combined with international market penetration, drives revenue per share of $55.57. Analyst consensus targets $708.43 with a strong buy rating from 4 firms.

Risks encompass regulatory scrutiny in diagnostics and animal health products, intense competition from larger healthcare players, and macroeconomic headwinds such as reduced pet spending amid inflation. Mitigation comes from IDEXX's high barriers to entry via proprietary technology, 96.85% institutional ownership providing stability, and a beta of 1.55 balanced by diversified revenue streams across veterinary, livestock, and water segments. Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.

Company Overview

IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.

Fundamental Snapshot

Revenue: 4.4461B
EBITDA: 1.5459B
Gross Profit: 2.7589B
Operating Margin: 31.8%
Profit Margin: 24.6%
ROE: 72.9%
Book Value: $19.64
Beta: 1.549
52-Wk High: $769.98
52-Wk Low: $518.55
Avg Volume: 437.188K
PEG Ratio: 3.492

Frequently Asked Questions

What is IDEXX Laboratories' business model?

IDEXX Laboratories develops, manufactures, and distributes diagnostic products and services primarily for companion animal veterinary practices, with additional focus on livestock, poultry, water testing, and dairy markets. The company generates revenue through instrument sales, consumables, reference laboratory services, and software solutions, achieving TTM revenue of $4.45 billion and EPS of $13.56.

What are IDEXX's main revenue sources?

Primary revenue comes from the Companion Animal Group (veterinary diagnostics and software), followed by Livestock, Poultry and Dairy, and Water segments. TTM revenue reached $4.45 billion with gross profit of $2.76 billion, supported by 14.3% quarterly revenue growth and high-margin recurring consumables and lab services.

What competitive advantages does IDEXX have?

IDEXX benefits from proprietary diagnostic technology, extensive reference lab networks, and strong brand loyalty in veterinary markets, creating high switching costs. Its 24.6% profit margin, 41.85 trailing P/E, and 96.85% institutional ownership underscore its leadership position versus competitors in the diagnostics space.

What are the key risks for IDXX investors?

Key risks include regulatory changes in animal health and diagnostics, competition from larger firms, and sensitivity to economic cycles affecting pet ownership spending. The stock's beta of 1.55 amplifies volatility, though diversification across veterinary, livestock, and water testing helps mitigate sector-specific downturns; no dividend is currently paid.

What is the growth outlook for IDEXX?

IDEXX shows strong growth potential with 17.2% quarterly earnings growth, analyst target price of $708.43, and forward P/E of 38.46. Expansion in companion animal diagnostics and international markets, alongside 0.172 quarterly earnings growth, supports continued revenue and EPS expansion through 2026 and beyond.

Trading Data

Open: $539.47
Previous Close: $539.37
Day Range: $535.85 – $547.68
Volume: 437.283K
Shares Outstanding: 78.883M
Analyst Target: $708.43

Related Assets

Vertex Pharmaceuticals Inc

$477.36

+0.90%

ISRG

Intuitive Surgical Inc

$337.50

+1.65%

REGN

Regeneron Pharmaceuticals Inc

$656.01

+0.63%

Get Deeper Analysis

Ask Theo anything about IDXX — earnings, valuation, technicals, or portfolio fit.

Try HeyTheo Free

Company Overview

IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.

Fundamental Snapshot

Revenue: 4.4461B
EBITDA: 1.5459B
Gross Profit: 2.7589B
Operating Margin: 31.8%
Profit Margin: 24.6%
ROE: 72.9%
Book Value: $19.64
Beta: 1.549
52-Wk High: $769.98
52-Wk Low: $518.55
Avg Volume: 437.188K
PEG Ratio: 3.492

Theo Outlook

IDEXX Laboratories presents a bullish thesis supported by a market capitalization of $44.76 billion, a trailing P/E of 41.85, EPS of $13.56, and robust quarterly revenue growth of 14.3% alongside 17.2% earnings growth year-over-year. The premium valuation reflects strong profitability margins of 24.6% and operating margins of 31.8%, positioning the company for continued outperformance in the diagnostics sector. Forward P/E of 38.46 suggests analysts anticipate sustained earnings expansion.

Key catalysts include accelerating adoption of companion animal diagnostics, expansion into livestock and water testing markets, and consistent earnings momentum with the latest quarter ending March 31, 2026 showing positive growth trends. Product innovation in veterinary reference labs and point-of-care testing, combined with international market penetration, drives revenue per share of $55.57. Analyst consensus targets $708.43 with a strong buy rating from 4 firms.

Risks encompass regulatory scrutiny in diagnostics and animal health products, intense competition from larger healthcare players, and macroeconomic headwinds such as reduced pet spending amid inflation. Mitigation comes from IDEXX's high barriers to entry via proprietary technology, 96.85% institutional ownership providing stability, and a beta of 1.55 balanced by diversified revenue streams across veterinary, livestock, and water segments. Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.

Frequently Asked Questions

What is IDEXX Laboratories' business model?

IDEXX Laboratories develops, manufactures, and distributes diagnostic products and services primarily for companion animal veterinary practices, with additional focus on livestock, poultry, water testing, and dairy markets. The company generates revenue through instrument sales, consumables, reference laboratory services, and software solutions, achieving TTM revenue of $4.45 billion and EPS of $13.56.

What are IDEXX's main revenue sources?

Primary revenue comes from the Companion Animal Group (veterinary diagnostics and software), followed by Livestock, Poultry and Dairy, and Water segments. TTM revenue reached $4.45 billion with gross profit of $2.76 billion, supported by 14.3% quarterly revenue growth and high-margin recurring consumables and lab services.

What competitive advantages does IDEXX have?

IDEXX benefits from proprietary diagnostic technology, extensive reference lab networks, and strong brand loyalty in veterinary markets, creating high switching costs. Its 24.6% profit margin, 41.85 trailing P/E, and 96.85% institutional ownership underscore its leadership position versus competitors in the diagnostics space.

What are the key risks for IDXX investors?

Key risks include regulatory changes in animal health and diagnostics, competition from larger firms, and sensitivity to economic cycles affecting pet ownership spending. The stock's beta of 1.55 amplifies volatility, though diversification across veterinary, livestock, and water testing helps mitigate sector-specific downturns; no dividend is currently paid.

What is the growth outlook for IDEXX?

IDEXX shows strong growth potential with 17.2% quarterly earnings growth, analyst target price of $708.43, and forward P/E of 38.46. Expansion in companion animal diagnostics and international markets, alongside 0.172 quarterly earnings growth, supports continued revenue and EPS expansion through 2026 and beyond.